STOCK TITAN

Syndax (NASDAQ: SNDX) insider files to sell 17,159 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Syndax Pharmaceuticals insider Michael A. Metzger filed a notice of proposed sale under Rule 144 to sell 17,159 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $360,826.32. The shares were acquired on 02/06/2026 via restricted stock vesting as compensation. The planned sale is expected around 02/09/2026 on the NASDAQ. Over the prior three months, Metzger sold 7,412 common shares for gross proceeds of $152,836.18, also reported in the filing.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the latest Form 144 filing for SNDX disclose?

The Form 144 shows insider Michael A. Metzger intends to sell 17,159 Syndax common shares, valued at $360,826.32, on NASDAQ through Fidelity. It also details prior three‑month sales and notes the shares came from restricted stock vesting as compensation.

How many Syndax (SNDX) shares is Michael A. Metzger planning to sell?

Michael A. Metzger plans to sell 17,159 common shares of Syndax. The filing lists an aggregate market value of $360,826.32 for this block, with the intended sale occurring around 02/09/2026 on NASDAQ via Fidelity Brokerage Services LLC.

How did Michael A. Metzger acquire the SNDX shares he plans to sell?

The 17,159 Syndax shares were acquired on 02/06/2026 through restricted stock vesting from the issuer as compensation. The filing identifies the nature of payment as “Compensation,” indicating they were not purchased for cash in the market.

What prior Syndax (SNDX) share sales has Michael A. Metzger reported?

Over the past three months, Metzger sold 7,412 Syndax common shares on 02/06/2026 for gross proceeds of $152,836.18. These historical transactions are listed alongside the new proposed sale in the disclosure schedule.

On which exchange and through which broker will the SNDX shares be sold?

The filing states the 17,159 Syndax common shares are expected to be sold on the NASDAQ. The designated broker is Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island, handling the planned Rule 144 transaction.

What is the approximate sale date in the SNDX Form 144 notice?

The notice lists an approximate sale date of 02/09/2026 for the 17,159 Syndax common shares. This date reflects when the insider expects to begin selling under Rule 144, subject to market conditions and applicable trading requirements.
Syndax Pharmaceuticals Inc

NASDAQ:SNDX

SNDX Rankings

SNDX Latest News

SNDX Latest SEC Filings

SNDX Stock Data

1.83B
85.79M
1.29%
120.98%
24.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK